ArticleVaccine2016
Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge.
Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- A Meta-Analysis of the Protective Efficacy ofMicroorganisms · 2026Article
- Brucellosis vaccine development: immunological mechanisms, animal models, and future directions.Archives of microbiology · 2026Review
- Disruption of the Nitric Oxide Reductase Operon viaMicroorganisms · 2025Article
- Parenteral Vaccination with a LiveMicroorganisms · 2024Article
- A Single Nasal Dose Vaccination with a Brucella abortus Mutant Potently Protects against Pulmonary Infection.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Brucellae as resilient intracellular pathogens: epidemiology, host-pathogen interaction, recent genomics and proteomics approaches, and future perspectives.Frontiers in veterinary science · 2023Review
- Live mucosal vaccination stimulates potent protectionFrontiers in immunology · 2022Article
- Evaluation of Brucellosis Vaccines: A Comprehensive Review.Frontiers in veterinary science · 2022Review
- Activation of mucosal immunity as a novel therapeutic strategy for combating brucellosis.Frontiers in microbiology · 2022Review
- Mucosal Vaccination Primes NK Cell-Dependent Development of CD8Frontiers in immunology · 2021Article
- Targeting resident memory T cell immunity culminates in pulmonary and systemic protection against Brucella infection.PLoS pathogens · 2020Article
- Immune Response to MucosalFrontiers in immunology · 2019Review
- Review of Requests to Exclude Attenuated Strains of Select Agents and Modified Select Toxins, Division of Select Agents and Toxins, Centers for Disease Control and Prevention, 2003-2017.Health security · 2018Article
- Development of new generation of vaccines forHeliyon · 2018Review
- Characterization of Brucella abortus mutant strain Δ22915, a potential vaccine candidate.Veterinary research · 2017Article
- Alternative strategies for vaccination to brucellosis.Microbes and infectionReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
There remains a need for an improved livestock vaccine for brucellosis since conventional vaccines are only ∼70% efficacious, making some vaccinated animals susceptible to Brucella infections. To address this void, a vaccine capable of evoking protective immunity, while still being sufficiently attenuated to produce minimal disease, is sought. In this pursuit, the ΔnorD ΔznuA B. abortus-lacZ (termed as znBAZ) was developed to be devoid of functional norD and znuA B. abortus genes, and to contain the lacZ as a marker gene. The results show that znBAZ is highly attenuated in mouse and human macrophages, and completely cleared from mouse spleens within eight weeks post-vaccination. Producing less splenic inflammation, znBAZ is significantly more protective than the conventional RB51 vaccine by more than four orders of magnitude. Vaccination with znBAZ elicits elevated numbers of IFN-γ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.